NASDAQ:PAVM PAVmed Q3 2026 Earnings Date & Estimates $2.41 -0.01 (-0.41%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.00 (+0.21%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. PAVmed is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from PAVmed in Q3 2026PAVmed is expected to post earnings of -$0.63 per share on revenue of $0.03 million. PAVmed last reported on May 14, 2026, posting -$1.17 per share and missing the -$0.69 consensus estimate.Consensus EstimatesConsensus EPS-$0.63Expected Revenue$0.03 millionRecent Track RecordLast ReportedQ1 2026Last Quarter EPS-$1.17 (Missed by -$0.48)Last Quarter Revenue$0.02 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ1 2026 Earnings ReportQ2 2024 Earnings ReportQ1 2024 Earnings Report PAVmed Q3 2026 Earnings FAQ When does PAVmed report Q3 2026 earnings? PAVmed (NASDAQ:PAVM) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is PAVmed's Q3 2026 earnings call? PAVmed's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for PAVmed? Analysts expect PAVmed to post earnings of -$0.63 per share for Q3 2026. How much revenue is PAVmed expected to report? The consensus revenue estimate for PAVmed is $0.03 million for Q3 2026. PAVmed Earnings HeadlinesAnalyzing InMode (NASDAQ:INMD) and PAVmed (NASDAQ:PAVM)October 8, 2026 | americanbankingnews.comLucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysSeptember 22, 2026 | prnewswire.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 16 at 1:00 AM | Behind the Markets (Ad)PAVmed Launches New At-the-Market Equity OfferingSeptember 10, 2026 | tipranks.comPAVmed (PAVM) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | finance.yahoo.comPAVmed Inc. Q2 2026 Earnings Call SummaryAugust 14, 2026 | finance.yahoo.comSee More PAVmed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PAVmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PAVmed and other key companies, straight to your email. Email Address About PAVmedPAVmed (NASDAQ:PAVM) is a medical device and diagnostics company focused on developing and commercializing technologies intended to improve the diagnosis and treatment of serious medical conditions. The company operates through subsidiaries and strategic business units that address areas including cancer detection, remote patient monitoring, vascular access and minimally invasive procedures. One of PAVmed’s primary businesses is its majority-owned subsidiary Lucid Diagnostics, which developed the EsoGuard DNA test and EsoCheck cell-collection device. The technologies are designed to help identify patients at elevated risk of esophageal precancer, including Barrett’s esophagus, and are marketed for use in the United States. PAVmed has also pursued products such as the PortIO implantable vascular access device and the CarpX minimally invasive carpal tunnel release system. Through Veris Health, PAVmed has also developed a remote monitoring platform intended to support cancer care by collecting and transmitting patient health information to care teams. The company was founded in 2014 and is led by Lishan Aklog, M.D., who serves as chairman and chief executive officer. Its operations and commercial activities are primarily focused on the U.S. healthcare market.View PAVmed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
